SSTN peptides that engage VLA-4 or VEGFR2 act as potent inhibitors of this mechanism and have significant potential, along with inhibitors of HPSE enzyme activity, as therapeutics to target cancer and other diseases that depend on this mechanism. This evidence concerns the gene KDR and cancer.